RE:RE:(TSE:PLI) latest ratings and price target changesI read it as such, at took it more of a type of reassurance in their previous findings.
Last of the 4 opening points stood out most. We've been saying it a long time here but seems now the thought is main stream.
"The current market capitalisation significantly undervalues the pipeline of ten drugs, of which 6 are rare diseases. We had raised our target to $6.7 to reflect 20% success rate of receiving approvals on at least one drug from each of the two platforms: PBI-4050 and PPPS."
How significant is significant? So if we had (in the eyes of PG) a 70% chance would that put as at the $23 mark?
A dreamer myself, here's to hoping Beacon is the closest without going over like the Price Is Right.